Low previous cardiovascular risk of patients with ST-elevation myocardial infarction

Gustavo Rodrigues1, Pedro de Araújo Gonçalves, Francisco Moscoso Costa

  • 1aHospital Centre of Western Lisbon (CHLO), Santa Cruz Hospital bChronic Diseases Research Center (CEDOC), Nova Medical School, Lisbon, Portugal.

Insights

The Systemic Coronary Risk Estimation (SCORE) tool underestimated cardiovascular risk in patients experiencing ST-elevation myocardial infarction (STEMI) as their first coronary artery disease (CAD) event. This highlights the need for improved risk stratification tools in primary prevention.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Public Health

Background:

  • Coronary artery disease (CAD) often presents initially as myocardial infarction.
  • Systemic Coronary Risk Estimation (SCORE) risk tables are standard for primary cardiovascular (CV) risk assessment.
  • Accurate CV risk stratification is crucial for effective primary prevention strategies.

Purpose of the Study:

  • To evaluate the performance of the SCORE risk charts in estimating CV risk for patients presenting with ST-elevation myocardial infarction (STEMI) as their first manifestation of CAD.
  • To assess the accuracy of pre-event SCORE calculations in identifying individuals at high risk for future cardiovascular events.

Main Methods:

  • Analysis of a prospective registry of 3056 patients with STEMI undergoing coronary angiography (2004-2014).
  • Inclusion of 1628 patients with STEMI as their first CAD manifestation, excluding those with prior CAD, high-risk equivalents, or normal coronaries.
  • Calculation of individual SCORE risk profiles using pre-event data for risk stratification into low, high, and very high-risk categories.

Main Results:

  • Over two-thirds of patients (71.4%) with STEMI as their first CAD event were classified as low risk (SCORE < 5%) prior to the event.
  • Only a small proportion (3.5%) were classified as very high risk (SCORE ≥ 10%).
  • The majority of STEMI patients, when assessed pre-event using SCORE, fell into lower risk categories than their actual event indicated.

Conclusions:

  • The SCORE risk charts significantly underestimate CV risk in patients experiencing STEMI as their first CAD manifestation.
  • Current risk stratification tools may not adequately identify individuals who will experience a first STEMI event.
  • There is a critical need for enhanced primary prevention strategies and additional tools to improve the identification of high-risk individuals for cardiovascular events.
Abstract

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.3K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
345
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
529
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
4.7K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
570